Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 30Neoplasms 5Lung Neoplasms 4Uveal Melanoma 2Melanoma 2Lymphoma, Large-Cell, Anaplastic 2Carcinoma 2ALK-positive NSCLC 2Solid Tumors 1Neuroblastoma 1Multiple Endocrine Neoplasia Type 2a 1Lymphoma 1Granuloma, Plasma Cell 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1Advanced Cancer 1Adenocarcinoma 1ALK or ROS1-positive NSCLC 1

Interventions

Nivolumab 19Ipilimumab 9linrodostat 6relatlimab 4Pemetrexed 4Paclitaxel 4Carboplatin 4ARRY-334543 4Docetaxel 3regorafenib 2anlotinib 2abemaciclib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Gemcitabine 2Cyclophosphamide 2Capecitabine 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1trametinib 1tislelizumab 1sargramostim 1ralimetinib 1prexasertib 1palifosfamide lysine 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1lirilumab 1indibulin 1gedatolisib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Cancer × Crizotinib × Clear all
NCT01576406 2018-10-25

Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients

Pfizer

Phase 1 Completed
88 enrolled 44 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡